Science News
from research organizations

Researchers discover an epigenetic lesion in hippocampus of Alzheimer's

Date:
January 21, 2014
Source:
IDIBELL-Bellvitge Biomedical Research Institute
Summary:
New research demonstrates, for the first time, the existence of an epigenetic lesion in the hippocampus of the brain of patients with Alzheimer's disease.
Share:
       
FULL STORY

In pink, location and structure of the brain hippocampus, region where it was found the epigenetic lesion in Alzheimer's patients.
Credit: IDIBELL-Bellvitge Biomedical Research Institute

Alzheimer's disease can reach epidemic range in the coming decades, by the increasing average age of society.There are two key issues for Alzheimer's disease: there is currently no effective treatment and it has been described very few associated genetic changes (mutations) which reduces the number of targets for future therapies.

Alzheimer's disease

Pathologically, Alzheimer 's disease is characterized by the accumulation of protein deposits in the brain of patients. These deposits are formed by plates of a protein called amyloid-beta and rolled tangles of tau protein . The root cause of these lesions in most cases is unknown, but specific alterations in regulating genes expression might be involved.

Today , the international journal in neurology Hippocampus publishes an article led by Manel Esteller, Director of Epigenetics and Cancer Biology , Institute of Biomedical Research of Bellvitge (IDIBEL) , ICREA researcher and Professor of Genetics at the University of Barcelona,with the collaboration of the Institute of Neuropathology IDIBELL led by Isidre Ferrer, demonstrating for the first time the existence of an epigenetic lesion in the hippocampus of the brain of patients with Alzheimer's.

Switches in the hippocampus

"We first started studying 30,000 molecular switches that turn on and off genes in the hippocampal region in the brains of Alzheimer patients in different stages of disease and compared with that of healthy patients of the same age. We note that dusp22 gene switches off (methylates) as the disease advances" explained Manel Esteller, director of the study.

"But more importantly" continues "was the discovery that this gene regulates tau protein. Perhaps therefore the accumulation of tau protein produced in the brain of patients with Alzheimer results from dusp22 epigenetic inactivation."

According Esteller "the finding is relevant not only to determine the causes of the disease, but also to test potential treatments in the future to act on these epigenetic molecular switches."


Story Source:

The above story is based on materials provided by IDIBELL-Bellvitge Biomedical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jose Vicente Sanchez-Mut, Ester Aso, Holger Heyn, Tadashi Matsuda, Christoph Bock, Isidre Ferrer, Manel Esteller. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus, 2014; DOI: 10.1002/hipo.22245

Cite This Page:

IDIBELL-Bellvitge Biomedical Research Institute. "Researchers discover an epigenetic lesion in hippocampus of Alzheimer's." ScienceDaily. ScienceDaily, 21 January 2014. <www.sciencedaily.com/releases/2014/01/140121130905.htm>.
IDIBELL-Bellvitge Biomedical Research Institute. (2014, January 21). Researchers discover an epigenetic lesion in hippocampus of Alzheimer's. ScienceDaily. Retrieved May 29, 2015 from www.sciencedaily.com/releases/2014/01/140121130905.htm
IDIBELL-Bellvitge Biomedical Research Institute. "Researchers discover an epigenetic lesion in hippocampus of Alzheimer's." ScienceDaily. www.sciencedaily.com/releases/2014/01/140121130905.htm (accessed May 29, 2015).

Share This Page: